Safety Study of Continued Enzalutamide Treatment in Prostate Cancer Patients (PLATO)
Safety Study of Continued Enzalutamide Treatment in Prostate Cancer Patients (PLATO). A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study of Continued Enzalutamide Treatment Beyond Progression in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Category & Conditions: Cancer
Medicine: Xtandi (enzalutamide)
ClinicalTrials.gov Identifier (NCT): NCT01995513
Protocol ID: MDV3100-10 (C3431013)
PrintDownloadOpen Plain Language Summary Result: Click here